| Basics |
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
|
| IPO Date: |
October 5, 2001 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.57B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.14 | 3.23%
|
| Avg Daily Range (30 D): |
$0.29 | 1.43%
|
| Avg Daily Range (90 D): |
$0.32 | 1.53%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.83M |
| Avg Daily Volume (30 D): |
1.17M |
| Avg Daily Volume (90 D): |
1.17M |
| Trade Size |
| Avg Trade Size (Sh.): |
147 |
| Avg Trade Size (Sh.) (30 D): |
69 |
| Avg Trade Size (Sh.) (90 D): |
65 |
| Institutional Trades |
| Total Inst.Trades: |
2,245 |
| Avg Inst. Trade: |
$2.71M |
| Avg Inst. Trade (30 D): |
$2.93M |
| Avg Inst. Trade (90 D): |
$2.92M |
| Avg Inst. Trade Volume: |
.22M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.47M |
| Avg Closing Trade (30 D): |
$4.87M |
| Avg Closing Trade (90 D): |
$4.82M |
| Avg Closing Volume: |
274.31K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$1.73
|
$.43
|
$.47
|
|
Diluted EPS
|
$1.65
|
$.41
|
$.45
|
|
Revenue
|
$ 558.5M
|
$ 146.56M
|
$ 141.42M
|
|
Gross Profit
|
$ 479.05M
|
$ 125.95M
|
$ 123.51M
|
|
Net Income / Loss
|
$ 208.67M
|
$ 52.11M
|
$ 56.74M
|
|
Operating Income / Loss
|
$ 243.42M
|
$ 66.3M
|
$ 63.37M
|
|
Cost of Revenue
|
$ 79.45M
|
$ 20.61M
|
$ 17.91M
|
|
Net Cash Flow
|
$ 277.11M
|
$ 135.25M
|
$ M
|
|
PE Ratio
|
12.75
|
|
|
|
|
|
